[HTML][HTML] The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed/refractory multiple …
Abstract Background BCMA-directed CAR T-cell therapy (CAR-T) has altered the treatment
landscape of relapsed/refractory (r/r) multiple myeloma, but is hampered by unique side …
landscape of relapsed/refractory (r/r) multiple myeloma, but is hampered by unique side …
The CAR-hematotox score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed/refractory multiple myeloma
Introduction: Hematological toxicity and infectious complications are both common and
substantially contribute to non-relapse mortality of CAR T-cell therapy. The recently …
substantially contribute to non-relapse mortality of CAR T-cell therapy. The recently …
Comparison of cilta-cel, an anti-BCMA CAR-T cell therapy, versus conventional treatment in patients with relapsed/refractory multiple myeloma
Background In the single-arm, phase 1b/2 CARTITUDE-1 study, ciltacabtagene autoleucel
(cilta-cel), an anti-B-cell maturation antigen chimeric antigen receptor T-cell (CAR-T) …
(cilta-cel), an anti-B-cell maturation antigen chimeric antigen receptor T-cell (CAR-T) …
Idecabtagene vicleucel (ide-cel; bb2121), a BCMA-targeted CAR T-cell therapy, in patients with relapsed and refractory multiple myeloma (RRMM): Initial KarMMa …
NC Munshi, LD Anderson, Jr, N Shah, S Jagannath… - 2020 - ascopubs.org
8503 Background: Outcomes are poor in triple-class exposed RRMM patients (pts) who
progress on immunomodulatory agents (IMiDs), proteasome inhibitors (PIs), and CD38 …
progress on immunomodulatory agents (IMiDs), proteasome inhibitors (PIs), and CD38 …
Matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the …
T Martin, SZ Usmani, JM Schecter, M Vogel… - Current Medical …, 2021 - Taylor & Francis
Objective This study estimated the comparative efficacy of ciltacabtagene autoleucel (cilta-
cel) versus the approved idecabtagene vicleucel (ide-cel) dose range of 300–460× 106 …
cel) versus the approved idecabtagene vicleucel (ide-cel) dose range of 300–460× 106 …
[HTML][HTML] Efficacy and Safety of CAR-T Therapy for Relapse or Refractory Multiple Myeloma: A systematic review and meta-analysis
Q Yang, X Li, F Zhang, Q Yang, W Zhou… - International Journal of …, 2021 - ncbi.nlm.nih.gov
Background: Multiple myeloma (MM) is incurable in spite of recent treatment improvements,
highlighting the development of new therapies. Chimeric antigen receptor (CAR) T-cell …
highlighting the development of new therapies. Chimeric antigen receptor (CAR) T-cell …
[HTML][HTML] Updated clinical and correlative results from the phase I CRB-402 study of the BCMA-targeted CAR T cell therapy bb21217 in patients with relapsed and …
Introduction: Idecabtagene vicleucel (ide-cel, bb2121) is the first chimeric antigen receptor
(CAR) T cell therapy approved for the treatment of relapsed or refractory multiple myeloma …
(CAR) T cell therapy approved for the treatment of relapsed or refractory multiple myeloma …
[HTML][HTML] Updated results from the phase I CRB-402 study of anti-BCMA CAR-T cell therapy bb21217 in patients with relapsed and refractory multiple myeloma …
M Alsina, N Shah, NS Raje, S Jagannath, D Madduri… - Blood, 2020 - Elsevier
Introduction: Chimeric antigen receptor (CAR) T cell therapy directed against B-cell
maturation antigen (BCMA) has shown promising results for the treatment of relapsed …
maturation antigen (BCMA) has shown promising results for the treatment of relapsed …
[HTML][HTML] Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T cell therapy, in patients with relapsed and refractory multiple myeloma: updated results …
Background: Ide-cel, a BCMA-directed CAR T cell therapy, showed tolerability and
promising efficacy in patients with relapsed and/or refractory multiple myeloma (RRMM) in …
promising efficacy in patients with relapsed and/or refractory multiple myeloma (RRMM) in …
[HTML][HTML] Factors associated with refractoriness or early progression after idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma: US Myeloma …
H Hashmi, DK Hansen, LC Peres, OC Puglianini… - …, 2024 - ncbi.nlm.nih.gov
While response rates and survival outcomes have been very promising for idecabtagene
vicleucel (ide-cel), a proportion of patients do not respond or relapse early after this B-cell …
vicleucel (ide-cel), a proportion of patients do not respond or relapse early after this B-cell …